FOLLOWUS
- Share with wechat friends or circle of friends
Immunosuppressive Treatment of Non-infectious Uveitis: History and Current Choices
- Affiliations：
Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
- Author bio：
*Corresponding author Tel/Fax: 86-10-69156351, E-mail: meifen_zhang531@hotmail.com
- Funds：
DOI：
中图分类号：-
纸质出版日期：2017-04
- Accepted：
Scan QR Code
Immunosuppressive Treatment of Non-infectious Uveitis: History and Current Choices[J]. 中国医学科学杂志（英文版）, 2017,32(1):48-61.
Zhao Chan, Zhang Meifen. Immunosuppressive Treatment of Non-infectious Uveitis: History and Current Choices[J]. Chinese medical sciences journal, 2017, 32(1): 48-61.
摘要
Abstract
Non-infectious uveitis is one of the leading causes of preventable blindness worldwide. Long-term immunosuppressive treatment is generally required to achieve durable control of inflammation in posterior and panuveitis. Although systemic corticosteroids have been the gold standard of immunosup- pressive treatment for uveitis since first introduced in 1950s
its side effects of long-term use often warrant an adjuvant treatment to reduce the dosage/duration of corticosteroids needed to maintain disease control. Conventional immunosuppressive drugs
classified into alkylating agent
antimetabolites and T cell inhibitors
have been widely used as corticosteroid-sparing agents
each with characteristic safety/tolerance profiles on different uveitis entities. Recently
biologic agents
which target specific molecules in immunopathogenesis of uveitis
have gained great interest as alternative treatments for refractory uveitis based on their favorable safety and effectiveness in a variety of uveitis entities. However
lack of large randomized controlled clinical trials
concerns about efficacy and safety of long-term usage
and economic burden are limiting the use of biologics in non-infectious uveitis. Local administration of immunosuppressive drugs (from corticosteroids to biologics) through intraocular drug delivery systems represent another direction for drug development and is now under intense investigation
but more evidences are needed to support their use as regular alternative treatments for uveitis. With the numerous choices belonging to different treatment modalities (conventional immunosuppressive agents
biologics and local drug delivery systems) on hand
the practice patterns have been reported to vary greatly from center to center. Factors influence uveitis specialists’ choices of immunosuppressive agents may be complex and may include personal familiarity
treatment availability
safety/tolerability
effectiveness
patient compliance
cost concerns and suggestions from related specialists such as rheumatologists and pediatricians. The focus of this review is to provide an overview of each treatment modality on safety/tolerability and effectiveness
which are believed to be the two most important factors affecting treatment decision making.
关键词
Keywords
references
Pleyer U , Sherif Z. Corticosteroids in ophthalmology. Ernst Schering Research Foundation workshop 2002 ; ( 40 ): 65 - 81 .
Sherif Z , Pleyer U. Corticosteroids in ophthalmology: past-present-future. Ophthalmologica 2002 ; 216 : 305 - 15 .
Blake EM , Fasanellarm RM , Wong AS. The effect of ACTH in glaucoma. Am J Ophthalmol 1950 ; 33 : 1231 - 5 .
Stern JJ. Acute glaucoma during cortisone therapy. Am J Ophthalmol 1953 ; 36 : 389 - 90 .
Black RL , Oglesby RB , Von SL , et al. Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA 1960 ; 174 : 166 - 71 .
Carnahan MC , Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 2000 ; 11 : 478 - 83 .
Stanbury RM , Graham EM. Systemic corticosteroid therapy—side effects and their management. Br J Ophthalmol 1998 ; 82 : 704 - 8 .
Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol 2001 ; 33 : 289 - 94 .
Jabs DA , Rosenbaum JT , Foster CS , et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000 ; 130 : 492 - 513 .
Jap A , Chee SP. Immunosuppressive therapy for ocular diseases. Curr Opin Ophthalmol 2008 ; 19 : 535 - 40 .
Elliott JH. Immunosuppressive therapy of ocular inflame- matory diseases: an alternative. Arch Ophthalmol 1969 ; 81 : 612 - 3 .
Hemady R , Tauber J , Foster CS. Immunosuppressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol 1991 ; 35 : 369 - 85 .
Sangwan VS. Treatment of uveitis: beyond steroids. Indian J Ophthalmol 2010 ; 58 : 1 - 2 .
Kruh J , Foster CS. The philosophy of treatment of uveitis: past, present and future. Dev Ophthalmol 2012 ; 51 : 1 - 6 .
Pujari SS , Kempen JH , Newcomb CW , et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 2010 ; 117 : 356 - 65 .
Pasadhika S , Kempen JH , Newcomb CW , et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol 2009 ; 148 : 500 - 9 .
Kacmaz RO , Kempen JH , Newcomb C , et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology 2010 ; 117 : 576 - 84 .
Okhravi N , Lightman S. Cystoid macular edema in uveitis. Ocul Immunol Inflamm 2003 ; 11 : 29 - 38 .
Posarelli C , Arapi I , Figus M , et al. Biologic agents in inflammatory eye disease. J Ophthalmic Vis Res 2011 ; 6 : 309 - 16 .
Thurau SR , Wildner G , Reiter C , et al. Treatment of endogenous uveitis with anti-CD4 monoclonal antibody: first report. Ger J Ophthalmol 1994 ; 3 : 409 - 13 .
Lim L , Suhler EB , Smith JR. Biologic therapies for inflammatory eye disease. Clin Exp Ophthalmol 2006 ; 34 : 365 - 74 .
Takeuchi M. A systematic review of biologics for the treatment of noninfectious uveitis. Immunotherapy 2013 ; 5 : 91 - 102 .
Babu K , Mahendradas P. Medical management of uveitis—current trends. Indian J Ophthalmol 2013 ; 61 : 277 - 83 .
Okada AA. The dream of biologics in uveitis. Arch Ophthalmol 2010 ; 128 : 632 - 5 .
Tempest-Roe S , Joshi L , Dick AD , et al. Local therapies for inflammatory eye disease in translation: past, present and future. BMC Ophthalmol 2013 ; 13 : 39 .
Riordan-Eva P , Lightman S. Orbital floor steroid injections in the treatment of uveitis. Eye 1994 ; 8 : 66 - 9 .
Ferrante P , Ramsey A , Bunce C , et al. Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylpred- nisolone in the management of posterior uveitis. Clin Experiment Ophthalmol 2004 ; 32 : 563 - 8 .
LeHoang P . The gold standard of noninfectious uveitis: corticosteroids. Dev Ophthalmol 2012 ; 51 : 7 - 28 .
Salek SS , Leder HA , Butler NJ , et al. Periocular triamcinolone acetonide injections for control of intraocular inflammation associated with uveitis. Ocul Immunol Inflamm 2013 ; 21 : 257 - 63 .
Leibowitz HM , Kupferman A. Periocular injection of corticosteroids: an experimental evaluation of its role in the treatment of corneal inflammation. Arch Ophthalmol 1977 ; 95 : 311 - 4 .
Rao NA , Rajeev B. Treatment of uveitis with immunosuppressive agents. Indian J Ophthalmol 1993 ; 41 : 107 - 13 .
Lustig MJ , Cunningham ET Jr. Use of immunosuppressive agents in uveitis. Curr Opin Ophthalmol 2003 ; 14 : 399 - 412 .
Dunn JP. Review of immunosuppressive drug therapy in uveitis. Curr Opin Ophthalmol 2004 ; 15 : 293 - 8 .
Imrie FR , Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007 ; 18 : 481 - 6 .
Durrani K , Zakka FR , Ahmed M , et al. Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. Surv Ophthalmol 2011 ; 56 : 474 - 510 .
Babu BM , Rathinam SR. Intermediate uveitis. Indian J Ophthalmol 2010 ; 58 : 21 - 7 .
Amon A , Pahl A , Szelenyi I. Can corticosteroids be beaten in future asthma therapy. Pharmazie 2006 ; 61 : 122 - 4 .
Bodor N , Buchwald P. Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids. Curr Pharm Des 2006 ; 12 : 3241 - 60 .
Comstock TL , Decory HH. Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Int J Inflam 2012 ; 2012 : 789623 .
Foster CS , Alter G , DeBarge LR, et al. Efficacy and safety of rimexolone 1% ophthalmic suspension vs . 1% prednisolone acetate in the treatment of uveitis. Am J Ophthalmol 1996 ; 122 : 171 - 82 .
Nussenblatt RB , Palestine AG , Chan CC. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 1983 ; 96 : 275 - 82 .
Kilmartin DJ , Forrester JV , Dick AD. Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet 1998 ; 352 : 35 - 6 .
Denniston AK , Dick AD. Systemic therapies for inflammatory eye disease: past, present and future. BMC Ophthalmol 2013 ; 13 : 18 .
Daniel E , Thorne JE , Newcomb CW , et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol 2010 ; 149 : 423 - 32 .
Esterberg E , Acharya NR. Corticosteroid-sparing therapy: practice patterns among uveitis specialists. J Ophthalmic Inflamm Infect 2012 ; 2 : 21 - 8 .
Yang P , Ren Y , Li B , et al. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Ophthalmology 2007 ; 114 : 606 - 14 .
Yang P , Fang W , Meng Q , et al. Clinical features of Chinese patients with Behcet's disease. Ophthalmology 2008 ; 115 : 312 - 8 .
Zhao C , Zhang MF , Dong FT , et al. Spectral domain optical coherence tomography of Vogt-Koyanagi-Harada disease: novel findings and new insights into the pathogenesis. Chin Med Sci J 2012 ; 27 : 29 - 34 .
Murphy CC , Greiner K , Plskova J , et al. Cyclosporine vs . tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 2005 ; 123 : 634 - 41 .
Gangaputra S , Newcomb CW , Liesegang TL , et al. Methotrexate for ocular inflammatory diseases. Ophthalmology 2009 ; 116 : 2188 - 98 .
Masuda K , Nakajima A , Urayama A , et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet 1989 ; 1 : 1093 - 6 .
Kempen JH , Newcomb CW , Nussenblatt RB , et al. Methotrexate vs . mycophenolate mofetil for ocular inflammatory diseases. Invest Ophthalmol Vis Sci 2012 ; 53 : 4169 .
Mudun BA , Ergen A , Ipcioglu SU , et al. Short-term chlorambucil for refractory uveitis in Behcet's disease. Ocul Immunol Inflamm 2001 ; 9 : 219 - 29 .
Akpek EK , Jabs DA , Tessler HH , et al. Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology 2002 ; 109 : 1506 - 13 .
Goldstein DA , Fontanilla FA , Kaul S , et al. Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology 2002 ; 109 : 370 - 7 .
Miserocchi E , Baltatzis S , Ekong A , et al. Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience. Ophthalmology 2002 ; 109 : 137 - 42 .
Foster CS , Wilson LA , Ekins MB. Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. Ophthalmology 1982 ; 89 : 340 - 53 .
Elder MJ , Lightman S , Dart JK. Role of cyclophosphamide and high dose steroid in ocular cicatricial pemphigoid. Br J Ophthalmol 1995 ; 79 : 264 - 6 .
Durrani K , Papaliodis GN , Foster CS. Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety. Ophthalmology 2004 ; 111 : 960 - 5 .
Saw VP , Dart JK , Rauz S , et al. Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology 2008 ; 115 : 253 - 61 .
Kruh J , Foster CS. Corticosteroid-sparing agents: conventional systemic immunosuppressants. Dev Ophthalmol 2012 ; 51 : 29 - 46 .
Nussenblatt RB , Palestine AG , Rook AH , et al. Treatment of intraocular inflammatory disease with cyclosporin A. Lancet 1983 ; 2 : 235 - 8 .
Nussenblatt RB , Palestine AG , Chan CC. Cyclosporine therapy for uveitis: long-term follow up. J Ocul Pharmacol 1985 ; 1 : 369 - 82 .
Nussenblatt RB , Palestine AG , Chan CC , et al. Effectiveness of cyclosporin therapy for Behcet's disease. Arthritis Rheum 1985 ; 28 : 671 - 9 .
Muftuoglu AU , Pazarli H , Yurdakul S , et al. Short term cyclosporin A treatment of Behcet's disease. Br J Ophthalmol 1987 ; 71 : 387 - 90 .
Le HP , Girard B , Deray G , et al. Cyclosporine in the treatment of birdshot retinochoroidopathy. Transplant Proc 1988 ; 20 : 128 - 30 .
Nussenblatt RB , Palestine AG , Chan CC , et al. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol 1991 ; 112 : 138 - 46 .
Towler HM , Cliffe AM , Whiting PH , et al. Low dose cyclosporin A therapy in chronic posterior uveitis. Eye 1989 ; 3 : 282 - 7 .
Deray G , Benhmida M , Le HP , et al. Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis. Ann Intern Med 1992 ; 117 : 578 - 83 .
Towler HM , Lightman SL , Forrester JV. Low-dose cyclosporin therapy of ocular inflammation: preliminary report of a long-term follow-up study. J Autoimmun 1992 ; 5 Suppl A : 259 - 64 .
Vitale AT , Rodriguez A , Foster CS. Low-dose cyclosporine therapy in the treatment of birdshot retinochoroidopathy. Ophthalmology 1994 ; 101 : 822 - 31 .
Dumont FJ. FK506, an immunosuppressant targeting calcineurin function. Curr Med Chem 2000 ; 7 : 731 - 48 .
Mochizuki M , Masuda K , Sakane T , et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 1993 ; 115 : 763 - 9 .
Ishioka M , Ohno S , Nakamura S , et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol 1994 ; 118 : 723 - 9 .
Sloper CM , Powell RJ , Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 1999 ; 106 : 723 - 8 .
Hogan AC , McAvoy CE, Dick AD, et al. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 2007 ; 114 : 1000 - 6 .
Lee RW , Greenwood R , Taylor H , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious uveitis. Ophthalmology 2012 ; 119 : 1223 - 30 .
Roesel M , Tappeiner C , Heiligenhaus A , et al. Oral voclosporin: novel calcineurin inhibitor for treatment of noninfectious uveitis. Clin Ophthalmol 2011 ; 5 : 1309 - 13 .
Schultz C. Voclosporin as a treatment for noninfectious uveitis. Ophthalmol Eye Dis 2013 ; 5 : 5 - 10 .
Zheng Y , Collins SL , Lutz MA , et al. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol 2007 ; 178 : 2163 - 70 .
Shanmuganathan VA , Casely EM , Raj D , et al. The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol 2005 ; 89 : 666 - 9 .
Phillips BN , Wroblewski KJ. A retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis. J Ophthalmic Inflamm Infect 2011 ; 1 : 29 - 34 .
Sen HN , Larson TA , Meleth AD , et al. Subconjunctival sirolimus for the treatment of chronic active anterior uveitis: results of a pilot trial. Am J Ophthalmol 2012 ; 153 : 1038 - 42 .
Nguyen QD , Ibrahim MA , Watters A , et al. Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect 2013 ; 3 : 32 .
Hemady RK , Baer JC , Foster CS. Immunosuppressive drugs in the management of progressive, corticosteroid-resistant uveitis associated with juvenile rheumatoid arthritis. Int Ophthalmol Clin 1992 ; 32 : 241 - 52 .
Davatchi F , Shams H , Shahram F , et al. Methotrexate in ocular manifestations of Behcet's disease: a longitudinal study up to 15 years. Int J Rheum Dis 2013 ; 16 : 568 - 77 .
Dev S , McCallum RM, Jaffe GJ. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 1999 ; 106 : 111 - 8 .
Lazar M , Weiner MJ , Leopold IH. Treatment of uveitis with methotrexate. Am J Ophthalmol 1969 ; 67 : 383 - 7 .
Samson CM , Waheed N , Baltatzis S , et al. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001 ; 108 : 1134 - 9 .
Kremer JM , Alarcon GS , Lightfoot RW Jr , et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994 ; 37 : 316 - 28 .
Hargreaves MR , Mowat AG , Benson MK. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. Thorax 1992 ; 47 : 628 - 33 .
Singh G , Fries JF , Spitz P , et al. Toxic effects of azathioprine in rheumatoid arthritis. A national post-marketing perspective. Arthritis Rheum 1989 ; 32 : 837 - 43 .
Yates CR , Krynetski EY , Loennechen T , et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997 ; 126 : 608 - 14 .
Gearry RB , Day AS , Barclay ML , et al. Azathioprine and allopurinol: a two-edged interaction. J Gastroenterol Hepatol 2010 ; 25 : 653 - 5 .
Goldstein LH , Dolinsky G , Greenberg R , et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol 2007 ; 79 : 696 - 701 .
Natekar A , Pupco A , Bozzo P , et al. Safety of azathioprine use during pregnancy. Can Fam Physician 2011 ; 57 : 1401 - 2 .
Doycheva D , Deuter C , Stuebiger N , et al. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol 2007 ; 91 : 180 - 4 .
Sobrin L , Christen W , Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology 2008 ; 115 : 1416 - 21, 1421 .
Bhat P , Cervantes-Castaneda RA , Doctor PP , et al. Mycophenolate mofetil therapy for sarcoidosis-associated uveitis. Ocul Immunol Inflamm 2009 ; 17 : 185 - 90 .
Rathore VM , Agrawal R , Chaudhary SP , et al. Mycophenolate mofetil therapy in uveitis: analysis of eight cases in a tertiary ophthalmic care centre in India. Int Ophthalmol 2009 ; 29 : 117 - 22 .
Chang PY , Giuliari GP , Shaikh M , et al. Mycophenolate mofetil monotherapy in the management of paediatric uveitis. Eye 2011 ; 25 : 427 - 35 .
Doycheva D , Zierhut M , Blumenstock G , et al. Long-term results of therapy with mycophenolate mofetil in chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 2011 ; 249 : 1235 - 43 .
Abu EAM , Hemachandran S , Al-Mezaine HS , et al. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease. Acta Ophthalmol 2012 ; 90 : e603 - 8 .
Siepmann K , Huber M , Stubiger N , et al. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis: a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol 2006 ; 244 : 788 - 94 .
Teoh SC , Hogan AC , Dick AD , et al. Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol 2008 ; 146 : 752 - 60, 760 .
Galor A , Jabs DA , Leder HA , et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 2008 ; 115 : 1826 - 32 .
Pasadhika S , Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics 2014 ; 8 : 67 - 81 .
Munoz-Fernandez S , Hidalgo V , Fernandez-Melon J , et al. Effect of infliximab on threatening panuveitis in Behcet's disease. Lancet 2001 ; 358 : 295 - 6 .
Reiff A , Takei S , Sadeghi S , et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001 ; 44 : 1411 - 5 .
Sfikakis PP , Theodossiadis PG , Katsiari CG , et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001 ; 358 : 295 - 6 .
Smith JR , Levinson RD , Holland GN , et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001 ; 45 : 252 - 7 .
Rosenbaum JT. Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis associated with Behcet's disease. J Rheumatol 2004 ; 31 : 1241 - 3 .
Murphy CC , Ayliffe WH , Booth A , et al. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004 ; 111 : 352 - 6 .
Braun J , Baraliakos X , Listing J , et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005 ; 52 : 2447 - 51 .
Kahn P , Weiss M , Imundo LF , et al. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006 ; 113 : 860 - 4 .
Lopez-Gonzalez R , Loza E , Jover JA , et al. Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study. Scand J Rheumatol 2009 ; 38 : 58 - 62 .
Baughman RP , Lower EE , Ingledue R , et al. Management of ocular sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2012 ; 29 : 26 - 33 .
Matsuda J , Kaburaki T , Kobayashi S , et al. Treatment of recurrent anterior uveitis with infliximab in patient with ankylosing spondylitis. Jpn J Ophthalmol 2013 ; 57 : 104 - 7 .
Zannin ME , Birolo C , Gerloni VM , et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year follow up data from the Italian Registry. J Rheumatol 2013 ; 40 : 74 - 9 .
Zmuda M , Tiev KP , Knoeri J , et al. Successful use of infliximab therapy in sight-threatening corticosteroid-resistant Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 2013 ; 21 : 310 - 6 .
Kruh JN , Yang P , Suelves AM , et al. Infliximab for the treatment of refractory noninfectious uveitis: a study of 88 patients with long-term follow-up. Ophthalmology 2014 ; 121 : 358 - 64 .
Iwata D , Namba K , Mizuuchi K , et al. Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behcet's disease with infliximab. Graefes Arch Clin Exp Ophthalmol 2012 ; 250 : 1081 - 7 .
Sieper J , Koenig A , Baumgartner S , et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 2010 ; 69 : 226 - 9 .
Zhang MF , Zhao C , Wen X , et al. The short-term efficacy and safety treatment study of recurrent uveitis in Behcet disease with etanercept. Zhonghua Yan Ke Za Zhi 2010 ; 46 : 145 - 50 .
Saeed MU , Raza SH , Goyal S , et al. Etanercept in methotrexate-resistant JIA-related uveitis. Semin Ophthalmol 2014 ; 29 : 1 - 3 .
Foster CS , Tufail F , Waheed NK , et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003 ; 121 : 437 - 40 .
Schmeling H , Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology 2005 ; 44 : 1008 - 11 .
Galor A , Perez VL , Hammel JP , et al. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006 ; 113 : 2317 - 23 .
Tynjala P , Lindahl P , Honkanen V , et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007 ; 66 : 548 - 50 .
Klotsche J , AUID-Oho , Niewerth M , et al. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Ann Rheum Dis 2015 ; 75 : 855 - 61 .
Suzuki J , Goto H. Uveitis associated with sarcoidosis exacerbated by etanercept therapy. Jpn J Ophthalmol 2009 ; 53 : 439 - 40 .
Kakkassery V , Mergler S , Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? Observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res 2010 ; 35 : 751 - 6 .
Vazquez-Cobian LB , Flynn T , Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr 2006 ; 149 : 572 - 5 .
Gueudry J , LeHoang P, Bodaghi B. Anti-tumor necrosis factor-alpha agents in noninfectious uveitis. Dev Ophthalmol 2012 ; 51 : 63 - 78 .
Diaz-Llopis M , Garcia-Delpech S , Salom D , et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 2008 ; 24 : 351 - 61 .
Kotaniemi K , Saila H , Kautiainen H. Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol 2011 ; 5 : 1425 - 9 .
Diaz-Llopis M , Salom D , Garcia-de-Vicuna C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 2012 ; 119 : 1575 - 81 .
Erckens RJ , Mostard RL , Wijnen PA , et al. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 2012 ; 250 : 713 - 20 .
Sen ES , Sharma S , Hinchcliffe A , et al. Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease—a case cohort interventional study. Rheumatology 2012 ; 51 : 2199 - 203 .
Dobner BC , Max R , Becker MD , et al. A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br J Ophthalmol 2013 ; 97 : 134 - 8 .
Magli A , Forte R , Navarro P , et al. Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 2013 ; 251 : 1601 - 6 .
Suhler EB , Lowder CY , Goldstein DA , et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol 2013 ; 97 : 481 - 6 .
Simonini G , Taddio A , Cattalini M , et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res 2011 ; 63 : 612 - 8 .
Ramanan AV , Dick AD , Benton D , et al. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials 2014 ; 15 : 14 .
Takase K , Ohno S , Ideguchi H , et al. Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease-related uveitis. Rheumatol Int 2011 ; 31 : 243 - 5 .
Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf 2005 ; 4 : 637 - 41 .
Palucka AK , Blanck JP , Bennett L , et al. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 2005 ; 102 : 3372 - 7 .
Plskova J , Greiner K , Muckersie E , et al. Interferon-alpha: a key factor in autoimmune disease. Invest Ophthalmol Vis Sci 2006 ; 47 : 3946 - 50 .
Durand JM , Soubeyrand J. Interferon-alpha 2b for refractory ocular Behcet's disease. Lancet 1994 ; 344 : 333 .
Feron EJ , Rothova A, van Hagen PM, et al. Interferon-alpha 2b for refractory ocular Behcet's disease. Lancet 1994 ; 343 : 1428 .
Kotter I , Eckstein AK , Stubiger N , et al. Treatment of ocular symptoms of Behcet's disease with interferon alpha 2a: a pilot study. Br J Ophthalmol 1998 ; 82 : 488 - 94 .
Wechsler B , Bodaghi B , Huong DL , et al. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet's disease. Ocul Immunol Inflamm 2000 ; 8 : 293 - 301 .
Kotter I , Zierhut M , Eckstein A , et al. Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behcet's disease with sight-threatening retinal vasculitis. Adv Exp Med Biol 2003 ; 528 : 521 - 3 .
Kotter I , Zierhut M , Eckstein AK , et al. Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003 ; 87 : 423 - 31 .
Gueudry J , Wechsler B , Terrada C , et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease. Am J Ophthalmol 2008 ; 146 : 837 - 44 .
Onal S , Kazokoglu H , Koc A , et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis. Arch Ophthalmol 2011 ; 129 : 288 - 94 .
Bodaghi B , Gendron G , Wechsler B , et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007 ; 91 : 335 - 9 .
Sleijfer S , Bannink M , Van Gool AR , et al. Side effects of interferon-alpha therapy. Pharm World Sci 2005 ; 27 : 423 - 31 .
Bolon B. Cellular and molecular mechanisms of autoimmune disease. Toxicol Pathol 2012 ; 40 : 216 - 29 .
Wahren-Herlenius M , Dorner T. Immunopathogenic mech- anisms of systemic autoimmune disease. Lancet 2013 ; 382 : 819 - 31 .
Gul A , Tugal-Tutkun I , Dinarello CA , et al. Interleukin-1 beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study. Ann Rheum Dis 2012 ; 71 : 563 - 6 .
Nussenblatt RB , Peterson JS , Foster CS , et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 2005 ; 112 : 764 - 70 .
Buggage RR , Levy-Clarke G , Sen HN , et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet's disease. Ocul Immunol Inflamm 2007 ; 15 : 63 - 70 .
Wroblewski K , Sen HN , Yeh S , et al. Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease. Can J Ophthalmol 2011 ; 46 : 322 - 8 .
Muselier A , Bielefeld P , Bidot S , et al. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm 2011 ; 19 : 382 - 3 .
Adan A , Mesquida M , Llorenc V , et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol 2013 ; 251 : 2627 - 32 .
Dick AD , Tugal-Tutkun I , Foster S , et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 2013 ; 120 : 777 - 87 .
Hong J , Liu Z , Sun X , et al. Secukinumab in the treatment of noninfectious uveitis. Ophthalmology 2013 ; 120 : e86 .
Tappeiner C , Heinz C , Specker C , et al. Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 2007 ; 39 : 184 - 6 .
Heiligenhaus A , Miserocchi E , Heinz C , et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab) . Rheu- matology 2011 ; 50 : 1390 - 4 .
Miserocchi E , Pontikaki I , Modorati G , et al. Rituximab for uveitis. Ophthalmology 2011 ; 118 : 223 - 4 .
Miserocchi E , Modorati G. Rituximab for noninfectious uveitis. Dev Ophthalmol 2012 ; 51 : 98 - 109 .
Dick AD , Meyer P , James T , et al. Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 2000 ; 84 : 107 - 9 .
Zulian F , Balzarin M , Falcini F , et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res 2010 ; 62 : 821 - 5 .
Elhai M , Deslandre CJ , Kahan A. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al. Arthritis Care Res 2011 ; 63:307-8; author reply 308.
Kenawy N , Cleary G , Mewar D , et al. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 2011 ; 249 : 297 - 300 .
Wadhwa S , Paliwal R , Paliwal SR , et al. Nanocarriers in ocular drug delivery: an update review. Curr Pharm Des 2009 ; 15 : 2724 - 50 .
Campochiaro PA , Hafiz G , Shah SM , et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010 ; 117 : 1393 - 9 .
Kempen JH , Altaweel MM , Holbrook JT , et al. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol 2010 ; 149 : 550 - 61 .
Kempen JH , Altaweel MM , Holbrook JT , et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology 2011 ; 118 : 1916 - 26 .
Klisovic DD. Mycophenolate mofetil use in the treatment of noninfectious uveitis. Dev Ophthalmol 2012 ; 51 : 57 - 62 .
关联资源
相关文章
相关作者
相关机构
- © 2024 中国医学科学院 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies